Amgen’s Imdelltra, a delta-like ligand 3 targeting Bispecific T-cell Engager (BiTE) therapy, was approved by the FDA in 2024 for pre-treated extensive-stage small cell lung cancer ...

Amgen is continuing to study Imdelltra in several trials, including some that will test the drug as an earlier line of treatment for small-cell lung cancer.

By Denny Jacob. Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer.

(RTTNews) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly extended median ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

THOUSAND OAKS, Calif., Sept. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRA TM (tarlatamab-dlle), a first-in-class delta-like ligand ...

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. ... Imdelltra is believed to have blockbuster potential, ...

The Food and Drug Administration on Thursday approved Amgen's treatment for patients with the most deadly form of lung cancer. The agency cleared the drug, called Imdelltra, as a second or later ...

Amgen's Imdelltra Shows Lower Risk of Death, Other Benefits in Phase 3 Trial Provided by Dow Jones Jun 2, 2025, 1:04:00 PM. By Denny Jacob .